

ACM BIOLABS ANNOUNCES NEW PARTNER

Singapore, 4th April 2018 – ACM Biolabs is happy to announce that on 26th January 2018 a patent application was filed with the US Patent and Trademark Office based on an invention jointly developed by scientists from the US Centers for Disease Control and Prevention (“**CDC**”) and ACM Biolabs. The application and any resulting patent(s) are co-owned by the CDC¹ and ACM Biolabs.

1. In the case of the CDC, its ownership rests with: The USA, as represented by the Secretary, Dept. of Health and Human Services.
-

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“ACM”) technology platform to allow its customers to develop diagnostics, therapeutics and vaccines targeting novel membrane proteins. ACM technology is being used by the world’s leading pharmaceutical companies to develop products requiring membrane proteins that are difficult or impossible to work with using traditional methods. ACM Biolabs has licensed technology from the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector agency for science, research and development, and from Nanyang Technological University (NTU) a research-intensive University in Singapore which is consistently ranked among the world’s best Universities.

About the US Centers for Disease Control and Prevention (“CDC”)

[CDC works 24/7](#) protecting America’s health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

Media Contact: info@ACMBiolabs.com